DUB targets explored
In the DUB field
Commercializing expert research into
Dubs and Ubiquitin pathway
Mission Therapeutics’ strategy is to create value by advancing its pipeline programs through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Selected programmes may be advanced in partnership with other pharmaceutical companies.
- Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone3rd December 2019
- BioMed Realty Announces First Lettings at Babraham Research Campus in Cambridge22nd October 2019
- Mission Therapeutics’ Collaboration with AbbVie Nominated for Scrip Best Partnership Alliance Award16th September 2019